Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 1/2020

RETROSPECTIVE STUDY ON ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS TREATMENT

FLORIN MAGHIAR 1, LAURA GRAȚIELA VICAȘ 2*, ANDREEA ARDELEAN 3, ALIN TEUȘDEA 4, OTILIA ANCA ȚICA 1, CLAUDIU OROS 2, MARIANA EUGENIA MUREȘAN 5

1.University of Oradea, Faculty of Medicine and Pharmacy, Medical Department, Oradea, Romania
2.University of Oradea, Faculty of Medicine and Pharmacy, Pharmacy Department, Oradea, Romania
3.“Dr. G. Curteanu” Municipal Clinical Hospital, Oradea, Romania
4.University of Oradea, Faculty of Environmental Protection, Oradea, Romania
5.University of Oradea, Faculty of Medicine and Pharmacy, Preclinical Disciplines Department, Oradea, Romania

Download Full Article PDF

The emergence of Captopril in 1977 marked the beginning of a new class of drugs for arterial hypertension: angiotensin-converting-enzyme-inhibitors (ACE inhibitors, ACE-I). This paper represents a retrospective study highlighting the risk/ benefit of using ACE inhibitors in patients. There were analysed the hospital records for 214 patients from the Municipal “Dr. G. Curteanu” Clinical Hospital, Oradea, Romania, in 2018 which were diagnosed with arterial hypertension and heart failure that were administered ACE inhibitors. The use of ACE inhibitors reduced the number of hospitalizations, therefore 86% of the patients didn’t need to be hospitalized again in 2018. In 84% of the patients, the healing condition has been improved at hospital discharge; we can say that ACE inhibitors and associated treatment were helpful in reducing clinical symptoms.